We've uncovered the 9 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
To own Avantor, you need to believe its position in lab supplies and bioprocessing can translate modest sales gains into healthier earnings, despite margin pressure and elevated leverage. The latest quarter supports the near term catalyst of improving VWR Distribution & Services growth and upgraded full year guidance, but the sharp drop in GAAP net income keeps the main risk front and center: profitability and cash generation remain under strain, limiting financial flexibility.
Among recent developments, the expanded NuSil collaboration with the Population Council on a three month dapivirine ring for HIV prevention is especially relevant. It highlights Avantor’s role in advanced therapies and complex formulations, tying directly into catalysts around bioprocessing, higher value products, and potential mix improvement, even as the core Lab Solutions and distribution earnings picture looks more pressured after the Q2 2026 results.
Yet while guidance is moving up, investors should be aware that Avantor’s elevated leverage and margin headwinds could still...
Read the full narrative on Avantor (it's free!)
Avantor's narrative projects $6.9 billion revenue and $566.4 million earnings by 2029.
Uncover how Avantor's forecasts yield a $10.31 fair value, a 25% downside to its current price.
The most optimistic analysts were assuming revenues around US$7.2 billion and earnings near US$535.8 million by 2029, far more upbeat than the margin pressure and customer concentration risks now in focus, so you should expect these views to evolve as fresh results come through.
Explore 2 other fair value estimates on Avantor - why the stock might be worth 25% less than the current price!
Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.
Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com